MedTrace Logo

Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic

NCT03968133 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-03-29

No results posted yet for this study

Summary

This study evaluates the use of an oral multi-strain probiotic in the treatment of anxiety in individuals with Parkinson's Disease. Participants will be randomized to either 12-week multi-strain probiotic treatment or placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

Probiotic

Oral probiotic delivered in powdered form.

DIETARY_SUPPLEMENT

Placebo

Oral placebo delivered in powdered form.

Sponsors & Collaborators

  • The W. Garfield Weston Foundation

    collaborator UNKNOWN

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Silke Appel-Cresswell, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2023-05-31
Completion
2023-12-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03968133 on ClinicalTrials.gov